EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double‐blind, placebo‐controlled trial

Vera Bril iD, Tomasz Berkowicz, Andrzej Szczudlik, Michael W Nicolle, Josef Bednarik, Petr Hon, Antanas Vaitkus, Tuan Vu iD, Csilla Rozsa, Tim Magnus, Gyula Panczel, Toomas Toomsoo und 13 weitere

Muscle & Nerve · 2025

DOI: 10.1002/mus.28289 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Muscle & Nerve, 2025. Verfasst von Vera Bril und 24 weiteren Autor:innen. Beteiligte Einrichtung: Toronto General Hospital, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Myasthenia Gravis, Immunoglobulins, Intravenous, Receptors, Cholinergic. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Grifols Therapeutics LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims Prospective, randomized, controlled trials of intravenous immunoglobulin (IVIG) maintenance therapy in myasthenia gravis (MG) are lacking. In this trial, we evaluated the safety and efficacy of caprylate/chromatography‐purified IVIG; (IGIV‐C) in patients with generalized MG undergoing standard care.

Methods

Sixty‐two patients enrolled in this phase 2, multicenter, international, randomized trial (1:1 IGIV‐C [2 g/kg loading dose; 1 g/kg every 3 weeks through week 21] or placebo). Efficacy was assessed by changes in Quantitative MG (QMG) score at week 24 versus baseline (primary endpoint) and percentage of patients with clinical improvement in QMG, MG Composite (MGC), and MG‐Activities of Daily Living (MG‐ADL) scores (secondary endpoints). Safety assessments reported all adverse events (AEs).

Results

The change in QMG at 24 weeks was −5.1 for IGIV‐C and −3.1 for placebo ( p = .187). Seventy percent of patients in the IGIV‐C group had improvement in MG‐ADL (≥2‐point decrease) versus 40.6% in the placebo group ( p = .025). Patients showing clinical improvement in QMG and MGC (≥3‐point decrease) were 70.0% for IGIV‐C versus 59.4% for placebo ( p = .442) and 60.0% for IGIV‐C versus 53.1% for placebo ( p = .610). IGIV‐C was well tolerated; serious AEs were similar between arms. Three of four MG exacerbations requiring hospitalizations occurred in the IGIV‐C arm with one death.

Discussion

Several efficacy parameters showed numerical results greater than those seen in the placebo group. This was a small study and may have been underpowered to see significant differences. Additional studies may be warranted to fully determine the efficacy of IVIG maintenance therapy in MG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisImmunoglobulins, IntravenousReceptors, CholinergicHumansMaleFemaleDouble-Blind MethodMiddle AgedAdultAgedTreatment OutcomeAutoantibodiesImmunologic FactorsActivities of Daily LivingProspective Studies

Stichwörter der Autor:innen

autoimmune diseaseintravenous immunoglobulinmyasthenia gravisneuromuscular disease

Substanzen

Immunoglobulins, IntravenousReceptors, CholinergicAutoantibodiesImmunologic Factors

Autor:innen und Institutionen

  • Toronto General Hospital, Toronto, Ontario, Canada.
  • III Miejskie Centrum Medyczne im, Dr Karola Jonschera w Łodzi, Lodz, Poland.
  • Centrum Neurologii Klinicznej, Krakow, Poland.
  • London Health Sciences Centre and Western University, London, Ontario, Canada.
  • Department of Neurology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Fakultni Nemocnice Ostrava, Neurologicka Klinika, Ostrava-Poruba, Czech Republic.

ORCID-Profile: Vera Bril, Tuan Vu, Tahseen Mozaffar

Förderung

  • Grifols Therapeutics LLC

Zitieren

APA

Bril, V., Berkowicz, T., Szczudlik, A., Nicolle, M. W., Bednarik, J., Hon, P., Vaitkus, A., Vu, T., Rozsa, C., Magnus, T., Panczel, G., Toomsoo, T., Pasnoor, M., Mozaffar, T., Freimer, M., Reuner, U., Vécsei, L., Souayah, N., Levine, T., …, & Mondou, E. (2025). Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double‐blind, placebo‐controlled trial. Muscle & Nerve. https://doi.org/10.1002/mus.28289

Vancouver

Bril V, Berkowicz T, Szczudlik A, Nicolle MW, Bednarik J, Hon P, et al. Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double‐blind, placebo‐controlled trial. Muscle & Nerve. 2025. doi:10.1002/mus.28289

BibTeX
@article{Bril2025,
  author = {Bril, Vera and Berkowicz, Tomasz and Szczudlik, Andrzej and Nicolle, Michael W and Bednarik, Josef and Hon, Petr and Vaitkus, Antanas and Vu, Tuan and Rozsa, Csilla and Magnus, Tim and Panczel, Gyula and Toomsoo, Toomas and Pasnoor, Mamatha and Mozaffar, Tahseen and Freimer, Miriam and Reuner, Ulrike and Vécsei, László and Souayah, Nizar and Levine, Todd and Pascuzzi, Robert M and Dalakas, Marinos C and Rivner, Michael and Griffin, Rhonda and Coll, Montse Querolt and Mondou, Elsa},
  title = {Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double‐blind, placebo‐controlled trial},
  journal = {Muscle & Nerve},
  year = {2025},
  doi = {10.1002/mus.28289}
}
Kostenlos starten →